Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lucitanib - Advenchen Laboratories/Shanghai Institute of Materia Medica

Next Previous
X
Search
Drug Profile

Lucitanib - Advenchen Laboratories/Shanghai Institute of Materia Medica

Alternative Names: AL 3810; CO-3810; E-3810 - Ethical Oncology Science; S-80881; S-80881-2

Latest Information Update: 22 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advenchen Laboratories; Shanghai Institute of Materia Medica
  • Developer Bristol-Myers Squibb; Clovis Oncology; HaiHe Biopharma; Servier; Shanghai Institute of Materia Medica
  • Class Acetamides; Antineoplastics; Cyclopropanes; Naphthalenes; Phenyl ethers; Quinolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Fibroblast growth factor receptor antagonists; Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c raf inhibitors; Proto-oncogene protein c-kit inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Small cell lung cancer
  • Phase II Gynaecological cancer; Malignant thymoma; Nasopharyngeal cancer; Solid tumours
  • Preclinical Mantle-cell lymphoma
  • Discontinued Breast cancer; Non-small cell lung cancer

Most Recent Events

  • 05 Apr 2024 Preclinical trials in Mantle-cell lymphoma in USA (unspecified route) prior to April 2024
  • 05 Apr 2024 Pharmacodynamics data from a preclinical study in Mantle-cell lymphoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 03 Jun 2022 Efficacy and safety data from phase II trial in LIO-1 trial in Gynaecological cancer presented at 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top